Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for rare blood disorder: drug trial targets anemia

NCT ID NCT05648968

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This phase 3 trial tests a drug called ianalumab against a placebo in 90 adults with warm autoimmune hemolytic anemia (wAIHA) who have already tried at least one treatment without success. The goal is to see if ianalumab can raise hemoglobin levels and keep them stable for at least eight weeks. Participants receive IV infusions of either the drug or a placebo, and researchers track their response over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ianalumab (a biologic drug given by IV infusion)
What this could lead to
If it works, this could offer a new treatment option for people with warm autoimmune hemolytic anemia who haven't responded to standard therapies.
What could go wrong
This is a phase 3 trial, but it's still experimental. The drug may not work better than placebo, and there could be side effects like infusion reactions or infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for WARM AUTOIMMUNE HEMOLYTIC ANEMIA (WAIHA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune hemolytic anemia, warm type

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

WARM AUTOIMMUNE HEMOLYTIC ANEMIA (WAIHA)

Contacts and locations

Locations

  • Fred Hutchinson Cancer Center

    Seattle, Washington, 98109, United States

  • Michigan Center of Medical Research

    Farmington Hills, Michigan, 48334, United States

  • Novartis Investigative Site

    CABA, Buenos Aires, C1414DRK, Argentina

  • Novartis Investigative Site

    Buenos Aires, C1039AAC, Argentina

  • Novartis Investigative Site

    Caba, C1015ABO, Argentina

  • Novartis Investigative Site

    Garran, Australian Capital Territory, 2605, Australia

  • Novartis Investigative Site

    Melbourne, Victoria, 3004, Australia

  • Novartis Investigative Site

    Guangzhou, Guangdong, 510515, China

  • Novartis Investigative Site

    Hangzhou, Zhejiang, 310003, China

  • Novartis Investigative Site

    Dalian, 116000, China

  • Novartis Investigative Site

    Tianjin, 300020, China

  • Novartis Investigative Site

    Tianjin, 300052, China

  • Novartis Investigative Site

    Créteil, 94010, France

  • Novartis Investigative Site

    Lille, 59037, France

  • Novartis Investigative Site

    Nantes, 44093, France

  • Novartis Investigative Site

    Nice, 06202, France

  • Novartis Investigative Site

    Dresden, 01307, Germany

  • Novartis Investigative Site

    Essen, 45147, Germany

  • Novartis Investigative Site

    Giessen, 35392, Germany

  • Novartis Investigative Site

    Hanover, 30161, Germany

  • Novartis Investigative Site

    Debrecen, Hajdu Bihar Megye, 4032, Hungary

  • Novartis Investigative Site

    New Delhi, National Capital Territory of Delhi, 110029, India

  • Novartis Investigative Site

    Madurai, Tamil Nadu, 625107, India

  • Novartis Investigative Site

    Hyderabad, Telangana, 500082, India

  • Novartis Investigative Site

    Lucknow, Uttar Pradesh, 226014, India

  • Novartis Investigative Site

    Kfar Saba, 4428164, Israel

  • Novartis Investigative Site

    Petah Tikva, 4941492, Israel

  • Novartis Investigative Site

    Milan, MI, 20100, Italy

  • Novartis Investigative Site

    Milan, MI, 20122, Italy

  • Novartis Investigative Site

    Bassano del Grappa, VI, 36061, Italy

  • Novartis Investigative Site

    Novara, 28100, Italy

  • Novartis Investigative Site

    Narita, Chiba, 286-8523, Japan

  • Novartis Investigative Site

    Matsuyama, Ehime, 7900024, Japan

  • Novartis Investigative Site

    Gifu, Gifu, 501-1194, Japan

  • Novartis Investigative Site

    Kobe, Hyōgo, 6500047, Japan

  • Novartis Investigative Site

    Isehara, Kanagawa, 259-1193, Japan

  • Novartis Investigative Site

    Suita, Osaka, 5650871, Japan

  • Novartis Investigative Site

    Itabashi-ku, Tokyo, 1738610, Japan

  • Novartis Investigative Site

    Shinjuku Ku, Tokyo, 160-0023, Japan

  • Novartis Investigative Site

    George Town, Pulau Pinang, 10450, Malaysia

  • Novartis Investigative Site

    Kuching, Sarawak, 93586, Malaysia

  • Novartis Investigative Site

    Johor Bahru, 80100, Malaysia

  • Novartis Investigative Site

    Singapore, 119074, Singapore

  • Novartis Investigative Site

    Singapore, S308433, Singapore

  • Novartis Investigative Site

    Barcelona, 08035, Spain

  • Novartis Investigative Site

    Murcia, 30008, Spain

  • Novartis Investigative Site

    Bangkok, 10330, Thailand

  • Novartis Investigative Site

    Bangkok, 10700, Thailand

  • Novartis Investigative Site

    Chiang Mai, 50200, Thailand

  • Novartis Investigative Site

    Birmingham, West Midlands, B15 2TH, United Kingdom

  • Novartis Investigative Site

    Leeds, LS1 3EX, United Kingdom

  • Novartis Investigative Site

    London, W12 0HS, United Kingdom

  • University of Minnesota Med Center

    Minneapolis, Minnesota, 55455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.